Locations:
SearchPatient input, clinical trials access are important program components
Providing access to promising therapies via clinical trials and getting patients’ input about treatment goals are essential to value-based care.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Translational research has to be front and center in what we do,” says Taussig Cancer Institute Chairman Brian J. Bolwell, MD, FACP of Cleveland Clinic Cancer Center. It’s also important that treatment plans align with what patients value in terms of outcomes, Dr. Bolwell says in this video, which is part of a series on value-based cancer care.
Click here to view more cancer related videos.
Photo Credit ©Russell Lee
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients